Sirtris pockets $37M in venture funds

Sirtris Pharmaceuticals of Cambridge, MA has gained $37 million in new funding, including $22 million in venture funds and $15 million in venture debt. The third round was led by new investor Bessemer Venture Partners and included Genzyme Ventures, among others. "Adding the expertise of a world class biopharmaceutical organization like Genzyme and the insight of leading investors like Bessemer and QVT further strengthens our ability to develop a new class of drugs to treat diseases of aging," said Christoph Westphal, M.D., Ph.D., CEO of Sirtris.

- read the release

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.